Sinusitis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Sinusitis – Drugs In Development, 2023’, provides an overview of the Sinusitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Sinusitis
- The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects
- The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sinusitis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sinusitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncABT Innovations Inc
Amgen Inc
Amytrx Therapeutics Inc
Aodh Lifesciences Pvt Ltd
AstraZeneca Plc
Beijing FuKangren Bio-pharm Tech Co Ltd
Bio-Thera Solutions Ltd
Blue Water Biotech Inc
Celltrion Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Diceros Therapeutics Inc
FUJIFILM Toyama Chemical Co Ltd
Furen Pharmaceutical Group Co Ltd
GeneOne Life Science Inc
Genrix (Shanghai) Biopharmaceutical Co Ltd
GlycoMira Therapeutics Inc
GSK plc
Insmed Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
JSR Life Sciences LLC
KeyMed Biosciences Inc
Lanier Biotherapeutics Inc
LianBio
Luye Pharma Group Ltd
Lyra Therapeutics Inc
Maxwell Biosciences Inc
MD Healthcare Inc
OptiNose Inc
Oticara Inc
Pfizer Inc
Pleros Therapeutics Inc
ProclaRx LLC
Quorum Innovations LLC
Recce Pharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
Sanofi
SaNOtize Research and Development Corp
Shandong Boan Biotechnology Co Ltd
Shanghai JMT-Bio Technology Co Ltd
Synermore Biologics Co Ltd
Trellis Bioscience LLC
Trove Therapeutics Inc
Upstream Bio Inc
Wuhan Yicheng Biotechnology Co Ltd